• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中毒性表皮坏死松解症中的皮肤T细胞募集。CD8 +淋巴细胞参与的进一步证据。

Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement.

作者信息

Correia O, Delgado L, Ramos J P, Resende C, Torrinha J A

机构信息

Department of Immunology, Faculty of Medicine, Hospital S João, Porto, Portugal.

出版信息

Arch Dermatol. 1993 Apr;129(4):466-8.

PMID:8466217
Abstract

BACKGROUND

Toxic epidermal necrolysis (TEN) is a life-threatening disease with severe mucocutaneous shedding. Although it is widely accepted that immune mechanisms are at play, the pathophysiology of TEN is still unknown. We studied the blister fluid inflammatory cells in three drug-related cases to further define the suspected T-cell involvement in TEN.

OBSERVATIONS

A peripheral blood lymphopenia, especially of CD4+ T lymphocytes, was associated with a high lymphocytic cellularity of the blister fluid. In two cases, immunophenotyping of blister fluid lymphocytes showed a predominance of the CD8 phenotype. Furthermore, using two-color flow cytometry in one patient, we could show the predominance of CD8+ CD29+ lymphocytes and CD45RA- negative cells.

CONCLUSIONS

Our findings point to a cutaneous recruitment of antigen-primed and cytotoxic T cells in TEN, further supporting the involvement of CD8+ lymphocytes in TEN pathogenesis and its immune mediation.

摘要

背景

中毒性表皮坏死松解症(TEN)是一种伴有严重黏膜皮肤脱落的危及生命的疾病。尽管免疫机制在其中起作用已被广泛认可,但TEN的病理生理学仍不清楚。我们研究了3例药物相关病例中的水疱液炎症细胞,以进一步明确TEN中疑似的T细胞参与情况。

观察结果

外周血淋巴细胞减少,尤其是CD4 + T淋巴细胞减少,与水疱液中淋巴细胞细胞密度高有关。在2例病例中,水疱液淋巴细胞的免疫表型分析显示CD8表型占优势。此外,在1例患者中使用双色流式细胞术,我们能够显示CD8 + CD29 +淋巴细胞和CD45RA阴性细胞占优势。

结论

我们的研究结果表明,TEN中存在抗原致敏和细胞毒性T细胞的皮肤募集,进一步支持CD8 +淋巴细胞参与TEN发病机制及其免疫介导作用。

相似文献

1
Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement.中毒性表皮坏死松解症中的皮肤T细胞募集。CD8 +淋巴细胞参与的进一步证据。
Arch Dermatol. 1993 Apr;129(4):466-8.
2
Impaired antigen presentation in toxic epidermal necrolysis.
Arch Dermatol. 1993 Jun;129(6):721-7.
3
Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine.卡马西平诱导中毒性表皮坏死松解症的机制研究
Arch Dermatol. 1994 May;130(5):598-604.
4
Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.中毒性表皮坏死松解症:效应细胞是药物特异性细胞毒性T细胞。
J Allergy Clin Immunol. 2004 Nov;114(5):1209-15. doi: 10.1016/j.jaci.2004.07.047.
5
The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.CD40/CD40配体系统在多形红斑及史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症谱系的皮肤损害中表达。
Br J Dermatol. 2006 Feb;154(2):319-24. doi: 10.1111/j.1365-2133.2005.07023.x.
6
T-cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T cells.药物性中毒性表皮坏死松解症中的T细胞亚群。CD8阳性T细胞诱导的可能致病机制。
Arch Dermatol. 1991 Jun;127(6):851-5.
7
In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption.固定型药疹演变过程中表皮内CD8 + T细胞和CD4 + T细胞的体内动态变化
Br J Dermatol. 2008 Jun;158(6):1230-8. doi: 10.1111/j.1365-2133.2008.08516.x. Epub 2008 Mar 20.
8
Animal models of toxic epidermal necrolysis.毒性表皮坏死松解症的动物模型。
J Dermatol. 2011 Mar;38(3):255-60. doi: 10.1111/j.1346-8138.2010.01173.x.
9
Lymphocyte subsets and Langerhans' cells in toxic epidermal necrolysis. Report of a case.中毒性表皮坏死松解症中的淋巴细胞亚群和朗格汉斯细胞。病例报告。
Arch Dermatol. 1986 Apr;122(4):455-8.
10
Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis.
Arch Dermatol. 1994 May;130(5):605-8.

引用本文的文献

1
Updates in the pathogenesis of SJS/TEN.史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症发病机制的最新进展。
Allergol Int. 2025 Jul;74(3):361-371. doi: 10.1016/j.alit.2025.05.002. Epub 2025 Jun 4.
2
A review of the immunogenetics of Stevens-Johnson syndrome and toxic epidermal necrolysis.史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的免疫遗传学综述。
Glob Med Genet. 2025 May 7;12(3):100054. doi: 10.1016/j.gmg.2025.100054. eCollection 2025 Sep.
3
Severe cutaneous drug toxicity following disitamab vedotin treatment for metastatic gastric cancer: a case report.
维迪西妥单抗治疗转移性胃癌后发生严重皮肤药物毒性:1例报告
Front Oncol. 2025 Jan 16;14:1504079. doi: 10.3389/fonc.2024.1504079. eCollection 2024.
4
Immune-related toxic epidermal necrolysis affecting trachea mucosal epithelium: a case report and literature review.免疫相关的中毒性表皮坏死松解症累及气管黏膜上皮:一例报告及文献复习
Front Pharmacol. 2024 Oct 18;15:1454015. doi: 10.3389/fphar.2024.1454015. eCollection 2024.
5
Clinical Features of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor versus Non-Immune Checkpoint Inhibitor Drugs in China: A Cross-Sectional Study and Literature Review.中国免疫检查点抑制剂与非免疫检查点抑制剂药物所致史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的临床特征:一项横断面研究及文献综述
J Inflamm Res. 2024 Oct 22;17:7591-7605. doi: 10.2147/JIR.S491791. eCollection 2024.
6
Spatial proteomics identifies JAKi as treatment for a lethal skin disease.空间蛋白质组学鉴定 JAKi 是治疗致命皮肤病的方法。
Nature. 2024 Nov;635(8040):1001-1009. doi: 10.1038/s41586-024-08061-0. Epub 2024 Oct 16.
7
Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions.严重皮肤不良反应的免疫病理学和基因组学研究进展。
J Allergy Clin Immunol. 2023 Feb;151(2):289-300.e4. doi: 10.1016/j.jaci.2022.12.005.
8
Clinical characteristics of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A single-center study.药物性史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的临床特征:一项单中心研究。
Asia Pac Allergy. 2022 Apr 21;12(2):e17. doi: 10.5415/apallergy.2022.12.e17. eCollection 2022 Apr.
9
Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report and Brief Review.PD-1抑制剂相关中毒性表皮坏死松解症的治疗:一例报告及简要综述
Onco Targets Ther. 2022 Apr 8;15:345-351. doi: 10.2147/OTT.S353743. eCollection 2022.
10
Sinopharm COVID-19 vaccine-induced Stevens-Johnson syndrome.国药新冠疫苗诱发史蒂文斯-约翰逊综合征。
J Fr Ophtalmol. 2022 Apr;45(4):e179-e182. doi: 10.1016/j.jfo.2021.12.005. Epub 2022 Jan 6.